DOVER, Del.–(BUSINESS WIRE)–Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR) (the “Company” or “Mana Capital”), a special purpose acquisition company (“Mana Capital”), today announced that for the purposes of achieving its previously announced business combination with Cardio Diagnostics, Inc. (“Cardio”), the Company has extended the date on which it is required to enter into a business combination for an additional period of one (1) month from August 26, 2022 until September 26, 2022, and that an amount of $216,667 has been deposited in the Company’s trust account (the “Trust Account”) in connection with the extension. The funds deposited in the trust account were provided by Cardio pursuant to the definitive merger agreement entered into by the parties on May 27, 2022. The purpose of the extension is to extend the time for Mana Capital and Cardio to complete the previously announced agreement. business combination. The Company’s incorporation documents allow for a total of 12 one-month extensions.
About Mana Capital Acquisition Corp.
Mana Capital Acquisition Corp. is a blank check corporation formed for the purpose of engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or several companies or entities. Its efforts to identify a potential target company will not be limited to any particular industry or geographic region, although it intends to focus its research on target companies operating in North America, Europe and Asia in healthcare, technology, green economy and consumer products sectors. sectors.
About Cardiac Diagnostics
Cardio Diagnostics is a biotechnology company that makes prevention and early detection of cardiovascular disease more accessible, personalized and accurate. Cardio was created to pursue the development and commercialization of an integrated genetic-epigenetic engine based on artificial intelligence (AI)MT for cardiovascular disease to become one of the leading medical technology companies to improve the prevention, early detection and aid in the treatment of cardiovascular disease.
Important information and where to find it
In connection with the proposed business combination, Mana Capital has filed a registration statement on Form S-4 containing proxy materials in the form of a proxy statement with the SEC. Form S-4 includes a proxy statement for distribution to holders of common stock of Mana Capital in connection with the solicitation of proxies by Mana Capital for the vote of Mana Capital shareholders in respect of the proposed business combination and other matters described in Form S-4, as well as the prospectus relating to the offer of securities to be issued to Cardio shareholders under the proposed Business Combination. Once Form S-4 has been declared effective, Mana Capital will mail a definitive proxy statement, when available, to its shareholders. Investors, security holders and other interested parties should read Form S-4, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available, because they will contain important information about Mana Capital, Cardio and the proposed business combination. In addition, Mana Capital will file other relevant documents with the SEC in connection with the business combination. Copies may be obtained free of charge from the SEC’s website at www.sec.gov. Securityholders of Mana Capital are urged to read Form S-4 and other relevant materials as they become available before making a voting decision with respect to the proposed business combination, as they will contain material on the business combination and the parties to the business. Combination.
Participants in the solicitation
Mana Capital and Cardio and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the proposed business combination under SEC rules. Securityholders may obtain more detailed information regarding the names, affiliations and interests of certain officers and directors of Mana Capital in the solicitation by reading Mana Capital’s Form S-4 and other relevant documents filed with the SEC in connection with the business combination when they become available. Information about the directors and senior officers of Mana Capital is set forth in Mana Capital’s Annual Report for the fiscal year ended December 31, 2021 on Form 10-K (the “Form 10-K”), which was filed with the SEC on March 31. , 2022. Information regarding persons who may, under SEC rules, be considered participants in the shareholder solicitation of the proposed business combination is set forth in Form S-4. These documents can be obtained free of charge at www.sec.gov.
Cardio and its directors and executive officers may also be considered participants in the solicitation of proxies from Mana Capital shareholders in connection with the proposed business combination. A list of the names of such directors and officers and information regarding their interests in the proposed business combination are included in Form S-4 filed in connection with the proposed business combination.
No offer or solicitation
This press release is not a proxy statement or a solicitation of a proxy, consent or authorization with respect to any securities or with respect to the proposed business combination and does not constitute an offer to sell or a solicitation of an offer to buy the securities of Mana Capital or Cardio, nor will there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful before the registration or qualification under the securities laws of such state or jurisdiction. No offer of securities will be made except by means of a prospectus satisfying the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The actual results of Mana Capital and Cardio may differ from their expectations, estimates and projections and, therefore, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “expect”, “anticipate”, “intend”, “plan”, “may”, “will” , “could”, “should”, “believes”, “predicts”, “potential”, “continues” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, Mana Capital’s and Cardio’s expectations regarding the future performance and expected financial impacts of the Business Combination, the satisfaction of the closing conditions of the Business Combination and the timing of the completion of the Business Combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are beyond the control of Mana Capital and Cardio and are difficult to predict. All forward-looking statements are based on estimates, forecasts and assumptions which, although considered reasonable by Mana Capital and its management, and Cardio and its management, as the case may be, are inherently uncertain and many factors could cause that actual results differ. materially current expectations which include, but are not limited to: the risks and uncertainties set forth in the sections entitled “Risk Factors” and “Caution Regarding Forward-Looking Statements” in Mana Capital’s Form S-1 (File No. 333-260360), Annual Report on Form 10-K for the fiscal year ended December 31, 2021, Quarterly Reports on Form 10-Q, and Registration Statement on Form S-4 with the SEC (File No. 333- 265308), as amended, which is subject to change and will include a document that serves as Mana Capital’s prospectus and proxy statement, and other documents filed by Mana Capital from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be taken as a representation by anyone that the forward-looking statements set forth herein will be realized or that any of the results contemplated by such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Mana Capital neither undertakes nor accepts any obligation or undertaking to release updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances about which such statement is made. based, unless otherwise required by law.